Oncotelic Participating at Biotechgate Digital Partnering
August 17, 2022 08:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including...
Oncotelic Announces Presentation of P001- OT-101 Phase 1/2 Trial in Pancreatic Cancer
July 12, 2022 07:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including...
Oncotelic Provides Update on OT-101 at the 2022 BIO International Convention
June 15, 2022 07:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including...
Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma (M201)
May 25, 2022 07:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), a developer of treatments for rare and orphan indications, including...
ONCOTELIC PROVIDES Q1 2022 FINANCIAL RESULTS COMPARED TO Q1 2021, PRODUCT DEVELOPMENT INITIATIVES AND CORPORATE UPDATE
May 23, 2022 11:14 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic”, “We” or the “Company”) (OTCQB:OTLC) today announced financial results for the three months ended...
Oncotelic Announces Pipeline Presentation and IPO Update of Sapu Therapeutics at the 2022 BIO International Convention
May 18, 2022 08:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including...
ONCOTELIC ANNOUNCES US PATENT GRANT FOR CA4P AND OXI4503 COMBINATION WITH CHECKPOINT INHIBITORS
May 11, 2022 07:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), is pleased to announce the grant of patent application no. 15/753,882...
Oncotelic Appoints Seymour Fein M.D. as Chief Regulatory Officer
May 04, 2022 07:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), today announced the appointment of Dr. Seymour Fein as its Chief...
Oncotelic Appoints Fatih Uckun, M.D., Ph.D., as Chief Medical Officer
May 03, 2022 07:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company” or “We”) (OTCQB:OTLC), today announced the appointment of Dr. Fatih Uckun as its...
ONCOTELIC PROVIDES YE 2021 FINANCIAL RESULTS COMPARED TO YE 2020, PRODUCT DEVELOPMET INITIATIVES AND CORPORATE UPDATE
April 18, 2022 07:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic”, “We” or the “Company”) (OTCQB:OTLC) today announced financial results for the full year ended...